Nonalcoholic Steatohepatitis clinical trials

Explore recruiting nonalcoholic steatohepatitis clinical trials.

Recruiting nonalcoholic steatohepatitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nonalcoholic Steatohepatitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

Spain, Belgium, Austria, Czechia, Portugal, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Pilot Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

17 β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis

Greece, Italy, Belgium, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

France, Italy, Germany, Spain, Poland, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis

Spain, Germany, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Nonalcoholic Steatohepatitis trials by city

Nonalcoholic Steatohepatitis in Toronto Nonalcoholic Steatohepatitis in Vancouver Nonalcoholic Steatohepatitis in Montreal Nonalcoholic Steatohepatitis in Calgary Nonalcoholic Steatohepatitis in Edmonton Nonalcoholic Steatohepatitis in Ottawa Nonalcoholic Steatohepatitis in Winnipeg Nonalcoholic Steatohepatitis in Quebec City Nonalcoholic Steatohepatitis in Hamilton Nonalcoholic Steatohepatitis in Kitchener Nonalcoholic Steatohepatitis in London Nonalcoholic Steatohepatitis in Halifax Nonalcoholic Steatohepatitis in New York Nonalcoholic Steatohepatitis in Los Angeles Nonalcoholic Steatohepatitis in Chicago Nonalcoholic Steatohepatitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease